Admission blood sugar levels tied to higher risk of CV/renal complications in COVID-19 patients

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-03-25 04:15 GMT   |   Update On 2022-03-25 04:20 GMT

UK: Admission blood sugar levels indicative of both hypo- and hyperglycemia is associated with increased odds of cardiovascular or renal complications in in individuals diagnosed with COVID-19, reveals a recent study. The results, published in the journal Diabetes Care, indicate the utility of admission glucose as a marker for risk stratification of high-risk patients. 

Tom Norris, Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, U.K, and colleagues conducted the study with an objective to investigate the association between admission blood glucose levels and risk of in-hospital cardiovascular and renal complications in a multicenter prospective study.

Advertisement

The study included 36,269 adults hospitalized with COVID-19 between 6 February 2020 and 16 March 2021 (N = 143,266). The associations between admission glucose level (mmol/L and mg/dL) and odds of in-hospital complications, including heart failure, cardiac ischemia, arrhythmia, cardiac arrest, stroke, coagulation complications, and renal injury were explored using logistic regression models. Restricted cubic splines were used to investigate nonlinearity. Interaction models explored whether associations between glucose levels and complications were modified by clinically relevant factors. 

Advertisement

The study revealed the following findings:

  • Cardiovascular and renal complications occurred in 10,421 (28.7%) patients; median admission glucose level was 6.7 mmol/L.
  • While accounting for confounders, for all complications except cardiac ischemia and stroke, there was a nonlinear association between glucose and cardiovascular and renal complications. For example, odds of heart failure, arrhythmia, coagulation complications, and renal injury decreased to a nadir at 6.4 mmol/L, 4.9 mmol/L, 4.7 mmol/L, and 5.8 mmol/L, respectively, and increased thereafter until 26.0 mmol/L, 50.0 mmol/L, 8.5 mmol/L, and 32.4 mmol/L.
  • Compared with 5 mmol/L, odds ratios at these glucose levels were 1.28 for heart failure, 2.23 for arrhythmia, 1.59 for coagulation complications, and 2.42 for renal injury.
  • For most complications, a modifying effect of age was observed, with higher odds of complications at higher glucose levels for patients age <69 years.
  • Preexisting diabetes status had a similar modifying effect on odds of complications, but evidence was strongest for renal injury, cardiac ischemia, and any cardiovascular/renal complication.

"We observed an increased odds of cardiovascular or renal complications for admission glucose levels indicative of both hypo- and hyperglycemia," wrote the authors. "Admission glucose could be used as a marker for risk stratification of high-risk patients. Further research should evaluate interventions to optimize admission glucose on improving COVID-19 outcomes."

Reference:

Tom Norris, Cameron Razieh, Thomas Yates, Francesco Zaccardi, Clare L. Gillies, Yogini V. Chudasama, Alex Rowlands, Melanie J. Davies, Gerry P. McCann, Amitava Banerjee, Annemarie B. Docherty, Peter J.M. Openshaw, J. Kenneth Baillie, Malcolm G. Semple, Claire A. Lawson, Kamlesh Khunti; on behalf of the ISARIC4C Consortium, Admission Blood Glucose Level and Its Association With Cardiovascular and Renal Complications in Patients Hospitalized With COVID-19. Diabetes Care 2022; dc211709. https://doi.org/10.2337/dc21-1709

KEYWORDS: Diabetes Care, blood sugar, COVID-19, hospitalization, renal, cardiovascular, complications, hyperglycemia, hypoglycemia, admission blood glucose, Tom Norris, renal injury, cardiac ischemia

Tags:    
Article Source : Diabetes Care

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News